Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects

Experimental: Drug:GZR-18 administered via subcutaneous injection
For Assigned Interventions: GZR-18 administered once via subcutaneous injection at doses of 1.0 ug/kg, 5.0 ug/kg, 10.0 ug/kg, 20.0 ug/kg, 30.0 ug/kg, 40.0 ug/kg & 50.0 ug/kg
Drug: GZR-18
As previously described in Arms

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 23, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments